therapeutic mouse anti ctla 4  (Bio X Cell)

Journal: Cancer immunology research

Article Title: Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

doi: 10.1158/2326-6066.CIR-19-0005

Figure Lengend Snippet: (A) Metastatic melanoma patients were treated with anti-CTLA-4 (ipilimumab) and non-responders were biopsied and then subsequently treated with anti-PD-1 (nivolumab or pembrolizumab). Patients were then evaluated for clinical outcome. Gene expression analyses were performed on biopsies from 4 anti-PD-1 responders and 5 non-responders. Significantly enriched metabolic pathways based on either (B) IPA and (C) GSEA analysis are shown. (D) Cutaneous melanoma patients whose information was included in TCGA were stratified in to two groups, high and low lymphocyte infiltration score. Gene Set enrichment analysis was performed and metabolic gene signature pathways (C2 MsigDB|GSEA) and GO (C5 MsigDB|GSEA) found enriched in patients with low compared to high lymphocytic score are presented.

Article Snippet: Therapeutic antibodies Anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14), and anti-PD-L1 (10F.9G2) were purchased from BioXCell (West Lebanon, NH) and administered intraperitoneally Patient cohort A cohort of 9 melanoma patients were included in the analysis.

Techniques: Expressing

Journal: Nature Communications

Article Title: Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

doi: 10.1038/ncomms14340

Figure Lengend Snippet: ( a ) Upregulation of CTLA-4 in CD8 + and Tcon lymphocytes in distant tumours. Median fluorescence intensity of CTLA-4 staining intensity is shown. ( b ) Treatment schema for combination therapy of NDV with CTLA-4 blockade in B16-F10 model with a larger tumour challenge (1 × 10 5 cells in each flank). ( c ) Growth of individual NDV-injected B16-F10 tumours. ( d ) Growth of individual distant B16-F10 tumours. ( e ) Overall survival in the B16-F10 model. ( f ) Survival of B16-F10 tumour re-challenge at 90 days with no further treatment. ( g ) Overall survival of combination therapy in the CT26 model. ( h ) Survival of CT26 tumour re-challenge at 90 days with no further treatment. * P <0.05, ** P <0.01, **** P <0.0001, NS, non-significant. ( a ) Representative data of two experiments with five animals per group. ( c – e ) Pooled data from three experiments with 5–10 animals per group. ( f ) Pooled data from five experiments with final number of 5–12 animals per group. ( g , h ) Pooled data from three experiments with 5–10 animals per group. Data with error bars represent mean±s.e.m. One way ANOVA was used for 4a,b and log-rank test was used for 4e–h.

Article Snippet: Therapeutic anti-CTLA-4 (clone 9H10) antibody and isotype control antibody was purchased from BioXcell (cat: BE0131 and BE0087).

Techniques: Fluorescence, Staining, Injection